Insect cell lines sales will strengthen through 2036, anchored by Sf9 at 46.0% of the product segment in 2026. The market was valued at USD 1.24 billion in 2025 and is expected to reach USD 4.07 billion by 2036, creating an incremental opportunity of USD 2.68 billion between 2026 and 2036.